Nexalin Technology, Inc. announced on February 18, 2025, that it received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD). This approval allows for clinical testing of its HALO™ Clarity headset in human subjects for the treatment of mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD).
This milestone follows a successful pilot testing protocol conducted with UCSD’s research team. UCSD has requested and will receive 50 HALO devices from Nexalin for this independent research project, with initial shipments already underway.
The HALO™ Clarity headset is powered by Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, designed to deliver non-invasive, deep-brain stimulation without drugs or invasive procedures. The independent study at UCSD will provide essential data to further establish HALO as a treatment option for military personnel and others suffering from mTBI and PTSD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.